Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | -$27.1M | -$41.4M |
| Net income | -$29.2M | -$39.9M |
| EPS (diluted) | -$16.31 | -$17.98 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$22.0M | -$32.7M |
| Capital expenditures | $1.99M | $789K |
| Free cash flow | -$24.0M | -$33.5M |
| Share buybacks | $0.00 | $1.45M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $16.3M | $96.4M |
| Total assets | $23.3M | $116M |
| Total liabilities | $11.2M | $10.2M |
| Shareholders' equity | -$60.5M | -$98.8M |
| Retained earnings | -$64.9M | -$105M |
| Shares (wtd avg diluted) | 1.79M | 2.22M |
Every figure is extracted from SpyGlass Pharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.